FDA gives Zytiga priority for chemo-naïve patients
This article was originally published in Scrip
Executive Summary
The US FDA has granted a priority review to the supplemental new drug application (sNDA) for Johnson & Johnson's Zytiga (abiraterone acetate) administered in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy.